Table 1.
Characteristics of 11 randomized placebo-controlled trials included in our systematic review
| Author, Year |
Duration ;
Week |
Age;Year | Design |
Status
menopause |
FSH
mIU/ml |
length of amenorrhea (months) | Isoflavone/mg |
Participants
Intervention |
Participants
control |
blinding method | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jeri, 2002 | 16 | 52 | P | Post | > 30 | >12 | 40 | 14 | 9 | Yes | ||
| Atkinson, 2004 | 51 | 55 | P | Peri-and post | > 30 | >12 | 40 | 86 | 91 | Yes | ||
| Lipovac, 2012 | 12×2 (wash out=1) | 53 | Co | Post | >35 | >12 | 80 | 50 | 59 | Yes | ||
| Baber, 1999 | 12×2 (wash out=4) | 54 | Co | Peri-and post | >30 | >6 | 40 | 43 | 44 | Yes | ||
|
Knight, 1999
. |
12 | 54 | P | Peri-and post | >40 U/l | ≥ 6 | 40 | 12 | 12 | Yes | ||
| Geller, 2009 | 12 | 52 | P | Peri-and post | >40 | >12 | 120 | 14 | 17 | Yes | ||
| van de Weijer, 2002 | 12 | 53 | P | Post | Not known | >12 | 80 | 15 | 11 | Yes | ||
| Tice, 2003 | 12 | 52 | P | Peri-and post | >30 | >6 | 82 | 84 | 85 | Yes | ||
| Giorno, 2010 | 24 | 53 | P | Post | > 30 | >12 | 40 | 50 | 50 | Yes | ||
| Ehsanpour, 2012 | 10 | 53 | P | post | Not mentioned | 12> | 45 | 28 | 27 | Yes | ||
| Hidalgo, 2005 | 12×2(wash out=1) | 51 | Co | Post | >30 | 12> | 80 | 53 | 53 | Yes | ||
Abbreviations; Post: post menopause; Peri: perimenopausal; Co: cross over; P: parallel; FSH: follicle stimulatin hormone